David Hsiehchen
Overview
Explore the profile of David Hsiehchen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lim M, Espinoza M, Huang Y, Franses J, Zhu H, Hsiehchen D
JAMA Netw Open
. 2025 Feb;
8(2):e2461735.
PMID: 39998829
Importance: Immunotherapies are the preferred frontline treatment for most hepatocellular carcinomas (HCCs), but only a small subset of patients attain complete responses to immunotherapies, resulting in an absence of radiographic...
2.
Magee D, Domenyuk V, Abraham J, Perdigones Borderias N, Swensen J, Solipuram P, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39932457
Purpose: Plasma-based liquid biopsy tests can detect tumor-specific genetic alterations and offer many advantages that complement tissue-based Comprehensive Genomic Profiling (CGP). However, age-related clonal hematopoiesis (CH) mutations can confound liquid...
3.
von Itzstein M, Liu J, Mu-Mosley H, Fattah F, Park J, Sorelle J, et al.
JTO Clin Res Rep
. 2024 Dec;
6(1):100751.
PMID: 39619775
Introduction: Racial and ethnic disparities in the presentation and outcomes of lung cancer are widely known. To evaluate potential factors contributing to these observations, we measured systemic immune parameters in...
4.
Hsiehchen D, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis E, et al.
Cancer Cell
. 2024 Nov;
42(12):1985-1987.
PMID: 39577419
Analysis of 27,810 patients with advanced cancers treated with anti-PD-1/L1 therapies shows that immune gene signatures or immune cell infiltration is not universally associated with mutation burden or long-term survivors...
5.
Song B, Wang K, Na S, Yao J, Fattah F, von Itzstein M, et al.
bioRxiv
. 2024 Jul;
PMID: 39005456
The interaction between antigens and antibodies (B cell receptors, BCRs) is the key step underlying the function of the humoral immune system in various biological contexts. The capability to profile...
6.
von Itzstein M, Liu J, Mu-Mosley H, Fattah F, Park J, Sorelle J, et al.
bioRxiv
. 2024 Jun;
PMID: 38915535
Introduction: Racial and ethnic disparities in the presentation and outcomes of lung cancer are widely known. To evaluate potential factors contributing to these observations, we measured systemic immune parameters in...
7.
Zhu M, Wang Y, Lu T, Guo J, Li L, Hsieh M, et al.
Cell Metab
. 2024 Jun;
36(8):1711-1725.e8.
PMID: 38901424
Somatic mutations in non-malignant tissues are selected for because they confer increased clonal fitness. However, it is uncertain whether these clones can benefit organ health. Here, ultra-deep targeted sequencing of...
8.
von Itzstein M, Yang Y, Wang Y, Hsiehchen D, Sheffield T, Fattah F, et al.
Front Immunol
. 2024 May;
15:1351739.
PMID: 38690281
Background: A useful clinical biomarker requires not only association but also a consistent temporal relationship. For instance, chemotherapy-induced neutropenia and epidermal growth-factor inhibitor-related acneiform rash both occur within weeks of...
9.
Muquith M, Espinoza M, Elliott A, Xiu J, Seeber A, El-Deiry W, et al.
Nat Cancer
. 2024 Mar;
5(7):1121-1129.
PMID: 38528112
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 or its ligand (PD-1/L1) have expanded the treatment landscape against cancers but are effective in only a subset of patients....
10.
Hsiehchen D, Beg M, Kainthla R, Lohrey J, Kazmi S, Khosama L, et al.
Nat Commun
. 2024 Mar;
15(1):2178.
PMID: 38467639
Immune checkpoint inhibitors targeting PD-1/L1 have modest efficacy in hepatocellular carcinoma as single agents. Targeting membranous phosphatidylserine may induce pro-inflammatory and -immune stimulating effects that enhance immunotherapy activity. This hypothesis...